RA
SCMP

Rational Advisors’s Sucampo Pharmaceuticals, Inc. SCMP Stock Holding History

Rational Advisors’s Portfolio SCMP Stock Details SCMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-6,700
Closed -$70K – 402
2017
Q2 		$70K Buy
+6,700
New +$68.3K 0.04% 248

Other funds holding SCMP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Rational Advisors's SCMP Position: Q3 2017 in Review

Rational Advisors sold out of Sucampo Pharmaceuticals, Inc. (SCMP) in Q3 2017, closing a stake of 6,700 shares — an estimated $70K sold.

Rational Advisors first reported a position in SCMP in Q2 2017 and held it in 1 quarter. The position peaked at $70K in Q2 2017. 178 funds tracked by Wall St. Rank hold SCMP as of Q3 2017.

  • Rational Advisors reported no remaining Sucampo Pharmaceuticals, Inc. position as of Q3 2017 after selling out during the quarter.
  • Rational Advisors sold 6,700 Sucampo Pharmaceuticals, Inc. shares in Q3 2017, an estimated $70K.
  • Rational Advisors first reported a position in Sucampo Pharmaceuticals, Inc. in Q2 2017 and held it in 1 quarter.
  • Rational Advisors's Sucampo Pharmaceuticals, Inc. position peaked at $70K in Q2 2017.
  • 178 funds tracked by Wall St. Rank held Sucampo Pharmaceuticals, Inc. as of Q3 2017.

Based on Rational Advisors's 13F filing for Q3 2017, filed 8 Nov 2017.